Welcome to our dedicated page for Nektar Therapeutics news (Ticker: NKTR), a resource for investors and traders seeking the latest updates and insights on Nektar Therapeutics stock.
Nektar Therapeutics (NKTR) is a clinical-stage biopharmaceutical company pioneering novel immunotherapies for autoimmune disorders and chronic inflammatory diseases. This dedicated news hub provides investors and researchers with timely updates on the company's scientific advancements and corporate developments.
Access authoritative information on NKTR's pipeline progress, including updates on rezpegaldesleukin (Treg stimulator) and NKTR-255 (IL-15 agonist). Our curated collection features press releases about clinical trial milestones, regulatory submissions, strategic partnerships, and financial disclosures.
Key content categories include therapy development breakthroughs, FDA communications, research collaborations, and manufacturing updates. All materials are sourced directly from official company channels to ensure accuracy and compliance.
Bookmark this page for streamlined access to NKTR's latest developments in polymer conjugate chemistry and immunomodulation research. Check regularly for updates that could inform your understanding of the company's scientific trajectory and market position.
Nektar Therapeutics (Nasdaq: NKTR) announced positive results from its REZOLVE-AD Phase 2b study of rezpegaldesleukin for moderate-to-severe atopic dermatitis at the EADV Congress. The study met its primary endpoint with significant mean improvement in EASI scores at week 16 across all treatment arms versus placebo.
The high dose (24 µg/kg q2w) demonstrated strong efficacy with 61% mean EASI improvement, 42% EASI-75 response, and 20% vIGA-AD 0/1 response. Notably, patients who crossed over from placebo showed deepening responses after 24 weeks, with EASI-75 reaching 62% and vIGA-AD 0/1 reaching 38%.
The drug showed a favorable safety profile with 60.3% treatment-emergent adverse events across treatment arms, comparable to placebo's 57.5%, and only 1.6% serious adverse events.
Nektar Therapeutics (NASDAQ:NKTR) has announced that results from its REZOLVE-AD Phase 2b study for rezpegaldesleukin in atopic dermatitis will be presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris.
The presentation will cover primary and secondary endpoints from the 16-week induction phase, including multiple patient-reported outcomes. Additionally, new data will be presented from placebo patients who crossed over to high-dose rezpegaldesleukin treatment. Dr. Jonathan Silverberg will deliver the late-breaker oral presentation on September 18th at 14:45.
Nektar Therapeutics (NASDAQ:NKTR) announced its participation in two upcoming investor conferences in September 2025. The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10 at 10:30 AM ET in New York City, and the Stifel Virtual Immunology and Inflammation Forum on September 15 at 2:30 PM ET.
Both presentations will be available via webcast through the company's investor relations website, with replays accessible for 30 days. Investors interested in one-on-one meetings with management can arrange them through their representatives.
Nektar Therapeutics (Nasdaq: NKTR) reported Q2 2025 financial results, with cash and investments of $175.9 million as of June 30, 2025, down from $269.1 million in December 2024. The company raised additional $107.5 million through a secondary offering in July 2025, extending operations into Q1 2027.
Key financial metrics include Q2 2025 revenue of $11.2 million (down from $23.5 million in Q2 2024) and a net loss of $41.6 million ($2.95 per share). The company reported significant progress with rezpegaldesleukin in Phase 2b studies for atopic dermatitis, achieving statistical significance in primary and secondary endpoints. The FDA granted Fast Track designation for rezpegaldesleukin in alopecia areata treatment.
Nektar Therapeutics (NASDAQ:NKTR) has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025, after U.S. market close. The company will host a conference call at 5:00 p.m. ET/2:00 p.m. PT, led by President and CEO Howard Robin.
Investors can access the audio-only webcast through the company's investor relations website at ir.nektar.com. The webcast replay will remain available until September 7, 2025. Participants wishing to join via phone must pre-register through the Nektar Earnings Call Registration link to receive dial-in information.
Nektar Therapeutics (NASDAQ:NKTR) has received Fast Track designation from the FDA for rezpegaldesleukin, targeting severe-to-very severe alopecia areata treatment in adults and children 12+ years weighing at least 40kg.
Rezpegaldesleukin is an investigational biologic therapy targeting the interleukin-2 receptor complex to stimulate regulatory T cells (Tregs) proliferation. The company expects to announce topline data from the REZOLVE-AA Phase 2b study in December 2025.
The Fast Track designation enables more frequent FDA interactions and potential eligibility for rolling and priority review, aiming to accelerate the development of treatments addressing unmet medical needs.
Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotech company, has successfully closed its public offering of common stock, raising $115 million in gross proceeds. The company sold 4,893,618 shares at $23.50 per share, including 638,298 additional shares from the full exercise of the underwriters' option.
The offering was managed by Jefferies and Piper Sandler as joint bookrunning managers, with BTIG and H.C. Wainwright & Co. also participating. The proceeds will support general corporate purposes, including research and development, clinical development, and manufacturing costs for advancing drug candidates.
Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company, has announced the pricing of its $100 million public offering of common stock. The company is offering 4,255,320 shares at a public price of $23.50 per share.
The offering includes a 30-day option for underwriters to purchase up to an additional 638,298 shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on July 2, 2025.
Nektar plans to use the net proceeds for general corporate purposes, including research and development, clinical development, and manufacturing costs to support its drug candidates. Jefferies and Piper Sandler are serving as joint bookrunning managers, with BTIG, LLC as passive bookrunner and H.C. Wainwright & Co. as co-manager for the offering.
Nektar Therapeutics (NASDAQ: NKTR), a clinical-stage biotechnology company specializing in immunotherapy, has announced a proposed underwritten public offering of common stock and pre-funded warrants. The offering includes an option for underwriters to purchase up to an additional 15% of common stock shares within 30 days.
The company plans to use the proceeds for general corporate purposes, including research and development, clinical development, and manufacturing costs to support its drug candidates. Jefferies and Piper Sandler are serving as joint bookrunning managers for the offering.
The securities will be offered through a shelf registration statement on Form S-3 (No. 333-286222) that was declared effective on April 1, 2025. The final size, terms, and completion of the offering remain subject to market conditions.
Nektar Therapeutics (Nasdaq: NKTR) announced significant positive results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin in treating moderate-to-severe atopic dermatitis. The study, involving 393 patients, met its primary endpoint with statistically significant improvements in EASI scores across all three dosing arms versus placebo (p<0.001).
Key achievements include 42% EASI-75 response in the high-dose group, significant improvements in itch relief, and positive outcomes in secondary endpoints including vIGA-AD and BSA scores. The drug demonstrated a favorable safety profile, with mainly mild-to-moderate injection site reactions as the most common side effect.
The company plans to continue the long-term maintenance study through Q1 2026, with additional Phase 2b data for alopecia areata expected in Q4 2025.
FAQ
What is the current stock price of Nektar Therapeutics (NKTR)?
What is the market cap of Nektar Therapeutics (NKTR)?
